Severe Raynaud's phenomenon with chronic hepatitis C disease treated with interferon

Pediatric Infectious Disease Journal

Volumn 22, Issue 2, 2003, Pages 195-197

  Iorio, Raffaele ^a   Spagnuolo, Maria Immacolata ^a   Sepe, Angela ^a   Zoccali, Stefania ^a   Alessio, Maria ^a   Vegnente, Angela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acrocyanosis; Extrahepatic manifestation; Hepatitis C virus; Raynaud's phenomenon

Indexed keywords

ALPHA2A INTERFERON; ATENOLOL; FLUNARIZINE; NIFEDIPINE;

ARTICLE; ASSAY; CASE REPORT; CHILD; CHRONIC HEPATITIS; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HUMAN; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SKIN ULCER;

BLOOD CHEMICAL ANALYSIS; CHILD, PRESCHOOL; CRYOGLOBULINEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; RAYNAUD DISEASE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER;

EID: 0037326249     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200302000-00021     Document Type: Article

References (15)

1. Hadziyannis SJ. Nonhepatic manifestations and combined diseases in HCV infection. Dig Dis Sci 1996;41:63S-74S.
2. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999;31:369-76.
3. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998;129:294-8.
4. Pawlotsky JM, Yahia MB, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8.
5. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients. Medicine 2000;79: 47-56.
6. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2 therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
7. Dammacco F, Samsonno D, Han JH, et al. Natural interferonalpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-43.
8. Roy V, Newland AC. Raynaud's phenomenon and cryoglobulinemia associated with the use of recombination human alpha-interferon. Lancet 1988;23:944-5.
9. Liozon E, Delaire L, Lacroix P, et al. Raynaud syndrome complicated by digital gangrene during treatment with interferon-alpha. Rev Med Intern 1997;18:316-9.
10. Duffy CN, Laxer RM, Lee P, Ramsay C, Fritzler M, Silverman ED. Raynaud syndrome in childhood. J Pediatr 1989;114:73-8.
11. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
12. Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992;38:798-802.
13. Maricq HR, Jennings JR, Valter I, et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling: Raynaud's Treatment Study Investigators. Vasc Med 2000;5:135-40.
14. Lamprecht P, Schnabel A, Gross WL. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon. Br J Rheumatol 1998;37:703-4.
15. Cacoub P, Ratziu V, Myers RP, et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol 2002;36:812-18.